Swine Influenza Vaccine

H1N1 and H3N2, Killed Virus

U.S. Patent No. 5,650,155 and 5,667,784 

• Protects against clinical disease associated with SIV. 
• Protects against clinical disease caused by SIV subtypes H1N1 and H3N2. 
• Significantly reduced lung lesions in challenge studies. 
• Produces excellent HI titers response for both H1N1 and H3N2 subtypes. 
• Serologically superior to autogenous vaccines. 
• Safe, tested in thousands of pigs (99.5% reaction free). 
• No reactions in pregnant sows, even given a double dose (4ml) at five and two weeks prefarrowing. 
• Formulated with Microsol Diluvac Forte^®, dual emulsion adjuvant, to optimize the immune response and high serological titers.   

Indications
For use in healthy swine as an aid in the prevention of influenza caused by serotype A swine influenza (sub-types H1N1 and H3N2). This product contains an inactivated US midwest field isolate of subytpe H3N2 and an inactivated subtype H1N1 of swine influenza type A virus in Microsol Diluvac Forte^® adjuvant.

Administration and Dosage
Shake well, aseptically inject intramuscularly (IM). Administer a 2.0 mL dose at 3 weeks of age or older, followed by one 2.0 mL dose 3 weeks later.

Caution

1. Store in the dark at not over 45^oF (7^oC).
2. Do not freeze.
3. Do not save partial contents.
4. Burn the container and all unused product.
5. Use in healthy swine.
6. Do not vaccinate within 60 days of slaughter.
7. Contains thimerosal and gentamicin as preservatives.
8. Allergic reactions may occur.
9. FOR VETERINARY USE ONLY.

Antidote
Epinephrine

Supplied
Code: PS-764-50
50 dose 100 mL